Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Dihydroartemisinin-Piperaquine

Small molecule · developed by GlaxoSmithKline

Phase 4 Most advanced trial (none active)
1 Registered trials

What is Dihydroartemisinin-Piperaquine?

Dihydroartemisinin-piperaquine is a fixed-dose combination antimalarial tablet containing 40 mg dihydroartemisinin and 320 mg piperaquine per tablet. It is studied for the treatment of malaria, including Plasmodium falciparum malaria.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Infectious disease
Developer
GlaxoSmithKline
In trials of
IBO
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 4

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05340153 Phase 4 Malaria Unknown IBO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Malaria

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.